COVID-19 immunotherapy / CEL-SCI - LARVOL DELTA

CEL-SCI to develop LEAPS COVID-19 immunotherapy in collaboration with University of Georgia Center for Vaccines and Immunology (Businesswire) - “CEL-SCI Corporation…announced today it has signed a collaboration agreement with the University of Georgia’s Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy.”

Licensing / partnership

Embattled Cel-Sci to tackle Covid-19 with immunotherapy platform tech LEAPS (FierceBiotech) - "Cel-Sci announced...it has formed a research partnership with the University of Georgia’s Center for Vaccines and Immunology to develop a drug candidate for patients at high risk of dying from COVID-19."

Licensing / partnership

CEL SCI : Initiates development of immunotherapy to treat Covid-19 coronavirus infection (Streetinsider.com) - "CEL-SCI Corporation...announces that it is developing an immunotherapy with the potential to treat the COVID-19 coronavirus using its patented LEAPS peptide technology....CEL-SCI is currently in discussion with multiple health care partners to expeditiously move this critically important work forward....CEL-SCI’s studies will utilize the LEAPS peptide approach...to elicit both a cell mediated antiviral response and an anti-inflammatory immunomodulating response by activating CD8 T lymphocytes."

Clinical